Colorectal cancer (CRC) is one of the leading types of cancer worldwide. CRC development has been associated with the constitutive activation of signal transducer and activator of transcription 3 (STAT3). STAT3 is a master regulator of inflammation during cancer‑associated colitis, and becomes upregulated in CRC. In CRC, STAT3 is activated by IL‑6, among other pro‑inflammatory cytokines, inducing the expression of target genes that stimulate proliferation, angiogenesis and the inhibition of apoptosis. One of the main STAT3‑regulated inhibitors of apoptosis is survivin, which is a bifunctional protein that regulates apoptosis and participates in cell mitosis. Survivin expression is normally limited to foetal tissue; however, survivin is also upregulated in tumours. In silico and experimental analyses have shown that the STAT3 interactome is relevant during CRC progression, and the constitutive STAT3‑survivin axis participates in development of the tumour microenvironment and response to therapy. The presence of a STAT3‑survivin axis has been documented in CRC cohorts, and the expression of these molecules is associated with poor prognosis and a higher mortality rate in patients with CRC. Thus, STAT3, survivin, and the upstream activators IL‑6 and IL‑6 receptor, are considered therapeutic targets for CRC. Efforts to develop drugs targeting the STAT3‑survivin axis include the evaluation of phytochemical compounds, small molecules and monoclonal antibodies. In the present review, the expression, function and participation of the STAT3‑survivin axis in the progression of CRC were investigated. In addition, an update on the pre‑clinical and clinical trials evaluating potential treatments targeting the STAT3‑survivin axis is presented.

Related Articles